A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-07

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

NCT07154342

Allergic Rhinitis, Seasonal

RECRUITING PHASE3

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

NCT06315426

Allergic Rhinitis

ACTIVE_NOT_RECRUITING PHASE2

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

NCT06300203

Seasonal Allergic Rhinitis

RECRUITING PHASE2

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

NCT07199257

Allergic Rhinitis, Seasonal

NOT_YET_RECRUITING PHASE3

A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

NCT05470647

Allergic Rhinitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interleukin-4 receptor responders 1

Recombinant fully human anti-IL4Rα monoclonal antibody drug.

Group Type EXPERIMENTAL

GR1802 injection-1

Intervention Type BIOLOGICAL

subcutaneous，dose\*1

Interleukin-4 receptor responders 2

Recombinant fully human anti-IL4Rα monoclonal antibody drug.

Group Type EXPERIMENTAL

GR1802 injection-2

Intervention Type BIOLOGICAL

subcutaneous，dose\*2

Placebo

Recombinant fully human anti-IL4Rα monoclonal antibody drug.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

subcutaneous，dose\*2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GR1802 injection-1

subcutaneous，dose\*1

Intervention Type BIOLOGICAL

GR1802 injection-2

subcutaneous，dose\*2

Intervention Type BIOLOGICAL

Placebo

subcutaneous，dose\*2

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xeligekimab Xeligekimab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects meet the diagnosis of SAR which has been prevalent for at least 2 years, and: standard treatment regimen for SAR was ineffective or subjective symptom control was unsatisfactory in the subject; positive test for at least one allergen associated with the development of SAR; pre-baseline symptom episodes of ≥ 4 days/week and a baseline TNSS of ≥ 6 points.
2. Consent to highly effective contraception

Exclusion Criteria

1. Other nasal comorbidities or co-morbidities/states that may be present at the time of screening；
2. It is expected that subjects' exposure to allergens in their home or work environments may change significantly during the study period.
3. Patients with asthma requiring stable use of inhaled controlled medications;
4. Previous or current malignant tumor within 5 years prior to screening;
5. Presence of other acute or chronic diseases or abnormal laboratory tests at the time of screening that, in the investigator's assessment, may have a more serious impact on the efficacy or safety assessment of the subject;
6. Live/live attenuated vaccine within 3 months prior to baseline;
7. Subjects with very limited outdoor activity during the daytime, as inferred from their regular daily routine;
8. Unwillingness or inability to comply with the permitted and prohibited medication/treatment specifications of the study, inability to meet the pre-randomization drug elution cycle specified in the protocol;
9. Women who are pregnant or breastfeeding;
10. History of alcohol or drug abuse within 3 months prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No